Genmab A/S

Genmab A/S Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Genmab A/S (GMAB.CO) as of Oct 8, 2026 is 3.22. In the previous year, Net Debt to Free Cash Flow Ratio was -2.65 — a change of -221.59% (higher).

Net Debt/FCF

3.22

YoY

-221.59%

Last updated:

Net Debt to Free Cash Flow Ratio of Genmab A/S is 2025 3.22 . Net Debt to Free Cash Flow Ratio of Genmab A/S was 2024 -2.65 . It decreases by -221.59% higher compared to the previous year.

The Genmab A/S Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2016
-13.10 USD
Jan 1, 2019
-8.88 USD
Jan 1, 2020
-2.57 USD
Jan 1, 2021
-9.57 USD
Jan 1, 2022
-6.04 USD
Jan 1, 2023
-3.91 USD
Jan 1, 2024
-2.65 USD
Jan 1, 2025
3.22 USD
The Genmab A/S Net Debt/FCF history
YEARNet Debt/FCFYoY
3.22-221.59%
-2.65-32.26%
-3.91-35.35%
-6.04-36.86%
-9.57+272.04%
-2.57-71.03%
-8.88-32.23%
-13.10-33.96%
-19.84-57.32%
-46.48—
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Net Debt to Free Cash Flow Ratio of Genmab A/S is 3.22 in 2025.

Net Debt to Free Cash Flow Ratio of Genmab A/S changed from -2.65 to 3.22, representing a -221.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Genmab A/S

All Key Metrics — Genmab A/S